Lasofoxifene Tartrate

99.60%

Lasofoxifene Tartrate

质检下载产品说明书核磁下载 SDS 产品使用指南

品牌：源叶(MedMol)

产品编号：S84154 一键复制产品信息

CAS号：190791-29-8

分子式：C₃₂H₃₇NO₈

分子量：563.64

别名：酒石酸拉索昔芬;酒石酸拉锁昔酚以及各个中间体杂质;LASOFOXIFENE HCL;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1);Lasofoxifene tartrate;2-Naph

货号	规格	价格	上海	北京	珠海	重庆	武汉
S84154-5mg	99.60%	￥280.00 S84154-5mg ￥280.00 现货	7 7	-	-	-	-
S84154-10mg	99.60%	￥330.00 S84154-10mg ￥330.00 现货	3 3	-	-	-	-
S84154-50mg	≥99%	￥1200.00 S84154-50mg ￥1200.00 2-3天	0 货期：2-3天	-	-	-	-

大包装询价收藏产品

加入购物车

产品介绍参考文献质检证书(COA) 摩尔浓度计算器相关产品

产品描述：

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis

靶点：

Target: Estrogen Receptor;EstrogenReceptor/ERR

体内研究：

Lasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) decreases arthritis severity, by reducing cartilage oligomeric matrix protein (COMP), the serum marker of cartilage destruction and reducing serum IL-6 (inflammatory cytokine) levels. Lasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) protects against generalised bone loss in CIA by increasing trabecular bone mineral density (BMD), cortical thickness in mice. Lasofoxifene tartrate (5, and 10 mg/kg; s.c.; 5 day/week; for 70 d) exerts function of inhibiting primary tumor growth and reducing metastases to the lung and the liver in mice

参考文献：

1. Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2016 Mar;55(3):553-63. 2. Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19(7):1395-1405. 3. Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23(1):54.

溶解性：

DMSO : 83.33 mg/mL (147.84 mM; Need ultrasonic)

保存条件：

2-8℃

配置溶液浓度参考：

	1mg	5mg	10mg
1 mM	1.774 ml	8.871 ml	17.742 ml
5 mM	0.355 ml	1.774 ml	3.548 ml
10 mM	0.177 ml	0.887 ml	1.774 ml
50 mM	0.035 ml	0.177 ml	0.355 ml